The selective peroxisome proliferator–activated receptor‐delta agonist seladelpar reverses nonalcoholic steatohepatitis pathology by abrogating lipotoxicity in diabetic obese mice... von Haczeyni, Fahrettin, Wang, Hans, Barn, Vanessa, Mridha, Auvro R., Yeh, Matthew M., Haigh, W. Geoffrey, Ioannou, George N., Choi, Yun‐Jung, McWherter, Charles A., Teoh, Narcissus C.‐H., Farrell, Geoffrey C.

Volltext

Seladelpar efficacy and safety at 3 months in patients with primary biliary cholangitis: ENHANCE, a phase 3, randomized, placebo-controlled study von Hirschfield, Gideon M, Shiffman, Mitchell L, Gulamhusein, Aliya, Kowdley, Kris V, Vierling, John M, Levy, Cynthia, Kremer, Andreas E, Zigmond, Ehud, Andreone, Pietro, Gordon, Stuart C, Bowlus, Christopher L, Lawitz, Eric J, Aspinall, Richard J, Pratt, Daniel S, Raikhelson, Karina, Gonzalez-Huezo, Maria S, Heneghan, Michael A, Jeong, Sook-Hyang, Ladrón de Guevara, Alma L, Mayo, Marlyn J, Dalekos, George N, Drenth, Joost P H, Janczewska, Ewa, Leggett, Barbara A, Nevens, Frederik, Vargas, Victor, Zuckerman, Eli, Corpechot, Christophe, Fassio, Eduardo, Hinrichsen, Holger, Invernizzi, Pietro, Trivedi, Palak J, Forman, Lisa, Jones, David E J, Ryder, Stephen D, Swain, Mark G, Steinberg, Alexandra, Boudes, Pol F, Choi, Yun-Jung, McWherter, Charles A

Volltext

Seladelpar improved measures of pruritus, sleep, and fatigue and decreased serum bile acids in patients with primary biliary cholangitis von Kremer, Andreas E., Mayo, Marlyn J., Hirschfield, Gideon, Levy, Cynthia, Bowlus, Christopher L., Jones, David E., Steinberg, Alexandra, McWherter, Charles A., Choi, Yun‐Jung

Volltext

A Phase 3 Trial of Seladelpar in Primary Biliary Cholangitis von Hirschfield, Gideon M., Bowlus, Christopher L., Mayo, Marlyn J., Kremer, Andreas E., Vierling, John M., Kowdley, Kris V., Levy, Cynthia, Villamil, Alejandra, Ladrón de Guevara Cetina, Alma L., Janczewska, Ewa, Zigmond, Ehud, Jeong, Sook-Hyang, Yilmaz, Yusuf, Kallis, Yiannis, Corpechot, Christophe, Buggisch, Peter, Invernizzi, Pietro, Londoño Hurtado, Maria Carlota, Bergheanu, Sandrin, Yang, Ke, Choi, Yun-Jung, Crittenden, Daria B., McWherter, Charles A.

Volltext

A phase II, randomized, open-label, 52-week study of seladelpar in patients with primary biliary cholangitis von Bowlus, Christopher L, Galambos, Michael R, Aspinall, Richard J, Hirschfield, Gideon M, Jones, David E J, Dörffel, Yvonne, Gordon, Stuart C, Harrison, Stephen A, Kremer, Andreas E, Mayo, Marlyn J, Thuluvath, Paul J, Levy, Cynthia, Swain, Mark G, Neff, Guy W, Sheridan, David A, Stanca, Carmen M, Berg, Christoph P, Goel, Aparna, Shiffman, Mitchell L, Vierling, John M, Boudes, Pol, Steinberg, Alexandra, Choi, Yun-Jung, McWherter, Charles A

Volltext

A Randomized, Double‐Blind, Active‐ and Placebo‐Controlled Efficacy and Safety Study of Arhalofenate for Reducing Flare in Patients With Gout von Poiley, Jeffrey, Steinberg, Alexandra S., Choi, Yun‐Jung, Davis, Charles S., Martin, Robert L., McWherter, Charles A., Boudes, Pol F., Bays, H., Bolshoun, D., Bolster, E., Cheung, D., Cone, C., DeGarmo, R., Earl, J., El Asmar, I., Felber, D., Fitz‐Patrick, D., Gaffo, A., Gottschlich, G., Greenwald, J., Griffin, C., Guice, M., Harper, W., Hill, J., Huffman, C., Huling, R., Johnson, F., Kafka, S., Keane, J., Kirby, W., Kirstein, J., Kolettis, E., Lefebvre, G., Mabaquiao, A., Maynard, K., McIlwain, H., McNeill, R., Mehta, D., Montgomery, R., Morgan, C., Poiley, J., Powell, S., Radbill, K., Reschak, M., Surowitz, R., Tarro, J., Turner, M., Velazquez, F., Watkins, L., White, J., Williams, H., Wilson, J., Zaidi, F., Henein, S., Toma, A., Burtchuladze, T., Kartvelishvili, E., Kilasonia, L., Lagvilava, L., Shalamberidze, L., Tsiskarishvili, N.

Volltext

Open‐label, clinical trial extension: Two‐year safety and efficacy results of seladelpar in patients with primary biliary cholangitis von Mayo, Marlyn J., Vierling, John M., Bowlus, Christopher L., Levy, Cynthia, Hirschfield, Gideon M., Neff, Guy W., Galambos, Michael R., Gordon, Stuart C., Borg, Brian B., Harrison, Stephen A., Thuluvath, Paul J., Goel, Aparna, Shiffman, Mitchell L., Swain, Mark G., Jones, David E. J., Trivedi, Palak, Kremer, Andreas E., Aspinall, Richard J., Sheridan, David A., Dörffel, Yvonne, Yang, Ke, Choi, Yun‐Jung, McWherter, Charles A.

Volltext

Liver biopsy for assessment of suspected drug‐induced liver injury in metabolic dysfunction‐associated steatohepatitis clinical trials: Expert consensus from the Liver Forum von Palmer, Melissa, Kleiner, David E., Goodman, Zachary, Brunt, Elizabeth, Avigan, Mark I., Regev, Arie, Hayashi, Paul H., Lewis, James H., Mehta, Ruby, Harrison, Stephen A., Siciliano, Massimo, McWherter, Charles A., Vuppalanchi, Raj, Behling, Cynthia, Miller, Veronica, Chalasani, Naga, Sanyal, Arun J.

Volltext

Featured Cover von Mayo, Marlyn J., Vierling, John M., Bowlus, Christopher L., Levy, Cynthia, Hirschfield, Gideon M., Neff, Guy W., Galambos, Michael R., Gordon, Stuart C., Borg, Brian B., Harrison, Stephen A., Thuluvath, Paul J., Goel, Aparna, Shiffman, Mitchell L., Swain, Mark G., Jones, David E. J., Trivedi, Palak, Kremer, Andreas E., Aspinall, Richard J., Sheridan, David A., Dörffel, Yvonne, Yang, Ke, Choi, Yun‐Jung, McWherter, Charles A.

Volltext

Seladelpar (MBX-8025), a selective PPAR-δ agonist, in patients with primary biliary cholangitis with an inadequate response to ursodeoxycholic acid: a double-blind, randomised, pla... von Jones, David, Boudes, Pol F, Swain, Mark G, Bowlus, Christopher L, Galambos, Michael R, Bacon, Bruce R, Doerffel, Yvonne, Gitlin, Norman, Gordon, Stuart C, Odin, Joseph A, Sheridan, David, Wörns, Markus-Alexander, Clark, Virginia, Corless, Linsey, Hartmann, Heinz, Jonas, Mark E, Kremer, Andreas E, Mells, George F, Buggisch, Peter, Freilich, Bradley L, Levy, Cynthia, Vierling, John M, Bernstein, David E, Hartleb, Marek, Janczewska, Ewa, Rochling, Fedja, Shah, Hemant, Shiffman, Mitchell L, Smith, John H, Choi, Yun-Jung, Steinberg, Alexandra, Varga, Monika, Chera, Harinder, Martin, Robert, McWherter, Charles A, Hirschfield, Gideon M

Volltext

OP-1 LONG-TERM EFFICACY AND SAFETY OF OPEN-LABEL SELADELPAR TREATMENT IN PATIENTS WITH PRIMARY BILIARY CHOLANGITIS: INTERIM 2-YEAR RESULTS FROM THE ASSURE STUDY von Trivedi, Palak J., Levy, Cynthia, Kowdley, Kris V., Gordon, Stuart C., Bowlus, Christopher L., Hurtado, Maria Carlota Londoño, Hirschfield, Gideon M., Gulamhusien, Aliya F., Lawitz, Eric J., Villamil, Alejandra, Cetina, Alma Ladron de Guevara, Mayo, Marlyn J., Younes, Ziad H., Shibolet, Oren, Yimam, Kidist K., Pratt, Daniel S., Heo, Jeong, Morgera, Ulrike, Andreone, Pietro, Kremer, Andreas E., Corpechot, Christophe, Goel, Aparna, Peyton, Adam, Elbeshbeshy, Hany, Crittenden, Daria B., Heusner, Carrie, Proehl, Sarah, Zhou, Shuqiong, McWherter, Charles A.

Volltext

THU-119 Seladelpar treatment increases fatty acid beta-oxidation and serum carnitine levels in patients with primary biliary cholangitis consistent with increased expression of the... von Choi, Yun-Jung, Johnson, Jeff, McWherter, Charles A.

Volltext

SAT-177 Assessment of PPARdelta target engagement in mouse liver assessed by single nuclei sequencing following a single oral dose of seladelpar von Cable, Edward, Choi, Yun-Jung, Wu, Xia, Song, Jiangao, Johnson, Jeff, McWherter, Charles A.

Volltext

Design and Syntheses of Potent and Selective Dipeptide Inhibitors of Candida albicans Myristoyl-CoA:Protein N-Myristoyltransferase von Devadas, Balekudru, Zupec, Mark E, Freeman, Sandra K, Brown, David L, Nagarajan, Srinivasan, Sikorski, James A, McWherter, Charles A, Getman, Daniel P, Gordon, Jeffrey I

Volltext

323: SELADELPAR TREATMENT OF PATIENTS WITH PRIMARY BILIARY CHOLANGITIS (PBC) FOR 2 YEARS IMPROVES THE GLOBE PBC SCORE AND PREDICTS IMPROVED TRANSPLANT-FREE SURVIVAL von Hansen, Bettina E., Watkins, Elaine, Yang, Ke, Choi, Yun-Jung, Mcwherter, Charles A., Hirschfield, Gideon

Volltext

Seladelpar treatment reduces interleukin-31 and pruritus in patients with primary biliary cholangitis von Kremer, Andreas E, Mayo, Marlyn J, Hirschfield, Gideon M, Levy, Cynthia, Bowlus, Christopher L, Jones, David E, Johnson, Jeff D, McWherter, Charles A, Choi, Yun-Jung

Volltext

3 EFFICACY AND SAFETY OF SELADELPAR IN PATIENTS WITH PRIMARY BILIARY CHOLANGITIS IN THE ASSURE STUDY: INTERIM RESULTS von Levy, Cynthia, Gordon, Stuart C., Lawitz, Eric, Yimam, Kidist, Reddy, Gautham, Peyton, Adam, Zhuo, Shuqiong, Proehl, Sarah, Heusner, Carrie, Crittenden, Daria B., Mcwherter, Charles A.

Volltext

SAT-175 PPAR-delta activation with seladelpar regulates cholangiocyte inflammation von Wu, Xia, Chen, Yen-Wen, Song, Jiangao, Cable, Edward, Johnson, Jeff, Elliott, Joanne, Caballero-Camino, Francisco, Chen, Xin, Martin, Robert, Stebbins, Jeffrey, Bañales, Jesús M., McWherter, Charles A.

Volltext

Circular Permutation of Granulocyte Colony-Stimulating Factor von Feng, Yiqing, Minnerly, John C, Zurfluh, Linda L, Joy, William D, Hood, William F, Abegg, Ann L, Grabbe, Edith S, Shieh, Jeng-Jong, Thurman, Tammy L, McKearn, John P, McWherter, Charles A

Volltext

OS-019 Efficacy and safety of seladelpar in patients with primary biliary cholangitis and compensated liver cirrhosis in the open-label, long-term ASSURE safety study: interim resu... von Gordon, Stuart C, Jacobson, Ira, Younes, Ziad H., Silveira, Marina, Drenth, Joost P.H., Morgera, Ulrike, Dalekos, George, Heo, Jeong, Yang, Ke, Heusner, Carrie, Crittenden, Daria B., McWherter, Charles A.

Volltext